Cardio3 Biosciences tests stem cell therapy in Serbia
This article was originally published in Scrip
Executive Summary
Cardio3 Biosciences, a Belgian biotech firm, has started testing C-Cure, its leading product for the treatment of heart failure, in Serbia's Institute for Cardiovascular Diseases.